In this article, European Pharmaceutical Review’s Hannah Balfour explores some of big pharma’s latest developments in HIV treatment, with commentary from ViiV Healthcare’s Head of Research and Development, Kimberly Smith.
List view / Grid view
The approval of Cabenuva (cabotegravir and rilpivirine, injectable formulation) means HIV infected adults could receive once-monthly injections to manage their condition.
The European Commission approval of the long-acting injectable HIV treatment could transform the lives of people living with the disease.
Ten medicines have been recommended for marketing authorisation and 10 extensions of indication have been suggested by the EMA.